The characteristics of these inherited retinal diseases make it difficult to define objective, clinically meaningful outcomes that are sensitive enough to measure change over the course of a trial.
Huma Qamar, MD
Advertisement
Qamar is Chief Medical Officer at Ocugen, Inc.
Articles by Huma Qamar, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Port Delivery System Therapies in Retinal Vascular Diseases
2
Offline smartphone AI accurately detects DR, glaucoma, and AMD in real-world study
3
NeuroOp Guru: What a big data study reveals about NAION and stroke risk
4
Polyendocrine metabolic ovarian syndrome: looking past the reproductive system to the eye
5